EC
SUPN icon

Elequin Capital’s Supernus Pharmaceuticals SUPN Stock Holding History

Elequin Capital’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-44
Closed -$1K – 666
2022
Q2 		$1K Sell
44
-16
-27% -$458 ﹤0.01% 372
2022
Q1 		$2K Buy
+60
New +$1.84K ﹤0.01% 267

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Elequin Capital's SUPN Position: Q3 2022 in Review

Elequin Capital sold out of Supernus Pharmaceuticals (SUPN) in Q3 2022, closing a stake of 44 shares — an estimated $1K sold.

Elequin Capital first reported a position in SUPN in Q1 2022 and held it in 2 quarters. The position peaked at $2K in Q1 2022. 244 funds tracked by Wall St. Rank hold SUPN as of Q3 2022.

  • Elequin Capital reported no remaining Supernus Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Elequin Capital sold 44 Supernus Pharmaceuticals shares in Q3 2022, an estimated $1K.
  • Elequin Capital first reported a position in Supernus Pharmaceuticals in Q1 2022 and held it in 2 quarters.
  • Elequin Capital's Supernus Pharmaceuticals position peaked at $2K in Q1 2022.
  • 244 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2022.

Based on Elequin Capital's 13F filing for Q3 2022, filed 10 Nov 2022.